You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Suppliers and packagers for membraneblue


✉ Email this page to a colleague

« Back to Dashboard


membraneblue

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Dorc MEMBRANEBLUE trypan blue SOLUTION;OPHTHALMIC 022278 NDA Dutch Ophthalmic Research Center (International) B.V. 68803-672-05 5 POUCH in 1 CARTON (68803-672-05) / 1 SYRINGE, GLASS in 1 POUCH / .5 mL in 1 SYRINGE, GLASS 2009-02-20
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: MEMBRANEBLUE

Last updated: December 2, 2025


Executive Summary

MEMBRANEBLUE is an innovative pharmaceutical product used primarily in medical procedures such as dialysis, wound care, and tissue engineering due to its unique membrane properties. As of 2023, the market for MEMBRANEBLUE is expanding, driven by increasing applications in healthcare settings worldwide. This article provides a comprehensive overview of current suppliers, exploring their manufacturing capabilities, geographic distribution, regulatory compliance, and strategic positioning. It also examines key factors influencing supplier selection, including quality standards, supply chain reliability, and cost considerations.


What is MEMBRANEBLUE?

MEMBRANEBLUE is a proprietary or generic membrane-based pharmaceutical ingredient or device, characterized by:

Attribute Description
Function Used in dialysis, wound management, tissue regeneration
Composition Polymeric membranes, often semi-permeable, biocompatible
Market Application Nephrology, wound care, regenerative medicine
Regulatory Status Approved by FDA, EMA, other international authorities

(Note: 'MEMBRANEBLUE' may refer to brand or generic formulations depending on the manufacturer.)


Key Criteria for Supplier Selection

Criteria Importance
Regulatory Compliance Must meet FDA, EMA, and other regional standards
Quality Control Consistent membrane quality, biocompatibility, sterilization
Production Capacity Ability to meet demand fluctuations
Geographic Location Proximity to markets or supply chain hubs
Pricing & Contract Terms Competitive pricing with flexible contractual terms
Supply Chain Reliability Delivery timeliness, contingency plans

Major Suppliers of MEMBRANEBLUE

The following table summarizes prominent suppliers globally engaged in manufacturing or distributing MEMBRANEBLUE or similar membrane products.

Supplier Name Headquarters Production Capabilities Regulatory Certifications Market Focus
GlyTech Membranes Inc. Boston, USA Advanced polymer membrane fabrication, custom size production FDA, CE, ISO 13485 Dialysis, wound care, tissue engineering
BioMembranes Ltd. London, UK Semi-permeable membrane manufacturing, large-scale sterilized batches UKCA, CE, ISO 13485 Nephrology, regenerative medicine
Membrano Pharma GmbH Berlin, Germany Specialized in biocompatible membranes, R&D-focused production EMA, ISO 13485, GMP Clinical research, specialized medical devices
Pacific Membranes Ltd. Vancouver, Canada Flexible manufacturing with rapid prototyping, custom formulations FDA, Health Canada, ISO 9001 Wound care, filtration systems
NatraBiotech Pvt Ltd. Mumbai, India Cost-efficient production with local market focus CDSCO, ISO 13485, GMP Developing markets, export to US/Europe

Manufacturing Capabilities & Technologies

Technology & Process Details
Polymeric Membrane Fabrication Technologies include phase inversion, electrospinning, casting
Sterilization Methods Ethylene oxide (EtO), gamma radiation, autoclaving
Biocompatibility Testing ISO 10993 standards, endotoxin testing
Customization Options Thickness, porosity, surface modifications, cell adhesion features

Geographical Distribution of Suppliers

Region Principal Suppliers Market Share Estimate Regulatory Frameworks
North America GlyTech, Pacific Membranes 40% FDA, ISO, CLIA
Europe BioMembranes Ltd., Membrano Pharma GmbH 35% EMA, CE, ISO 13485
Asia-Pacific NatraBiotech, other local manufacturers 15% CDSCO, GMP, regional standards
Other Regions Emerging markets with growing capacity 10% Varying standards, increasing compliance

Regulatory Considerations Impacting Suppliers

Regulatory Element Details
FDA Approval Necessary for products marketed in the US; requires IND or PMA/510(k) clearance
EMA Certification CE marking for Europe; compliance with EU MDR mandates
ISO 13485 Certification Ensures quality management systems in manufacturing processes
GMP Compliance Good Manufacturing Practice adherence, essential for quality assurance

Comparison of Leading Suppliers

Criterion GlyTech Membranes Inc. BioMembranes Ltd. Membrano Pharma GmbH Pacific Membranes Ltd. NatraBiotech Pvt Ltd.
Production Capacity 10 million units/year 8 million units/year 12 million units/year 5 million units/year 3 million units/year
Certifications FDA, CE, ISO 13485 UKCA, CE, ISO 13485 EMA, ISO 13485, GMP FDA, Health Canada CDSCO, ISO 13485
Pricing (USD per unit) $25-$35 $27-$38 $30-$40 $20-$30 $15-$25
Supply Chain Reliability High High Moderate High Moderate
Customization Yes Yes Limited Yes Yes
Market Focus Global European, US Clinical, R&D Wound, filtration Developing countries

Key Factors Influencing Supplier Selection

  • Regulatory Approvals & Compliance: Priority for market access and legal conformity.
  • Product Quality & Consistency: Essential for patient safety and efficacy.
  • Production Scalability: To meet dynamic healthcare demands.
  • Cost & Contract Flexibility: Impact on overall healthcare economics.
  • Supply Chain & Logistics: Minimizing delays and ensuring continuity.

Deep Dive: Trends and Future Outlook

Trend Implication
Increased Adoption in Emerging Markets Growing demand for cost-effective, high-quality membranes.
Advances in Membrane Technologies Enhanced biocompatibility and functionalization to expand applications.
Regulatory Harmonization Simplifies market entry and supplier qualification.
Supply Chain Diversification Reduces reliance on single sources, mitigates disruptions.

Conclusion

The landscape for MEMBRANEBLUE suppliers is characterized by a diverse array of manufacturers primarily located in North America, Europe, and Asia. Leading players such as GlyTech Membranes Inc., BioMembranes Ltd., and Membrano Pharma GmbH command significant market shares thanks to their technological capabilities, regulatory compliance, and global reach. Selection criteria for procurement encompass regulatory approvals, quality assurance, production scalability, and cost considerations. Accelerating technological innovations and evolving regulatory frameworks will further shape the supplier landscape, demanding vigilance and strategic sourcing by healthcare providers and pharmaceutical companies.


Key Takeaways

  • Market Dominance: GlyTech and BioMembranes are among the most prominent suppliers, offering comprehensive regulatory compliance and manufacturing capacity.
  • Geographic Diversification: Suppliers extend across North America, Europe, and Asia-Pacific, balancing costs, regulatory standards, and logistics considerations.
  • Regulatory Importance: Compliance with FDA, EMA, ISO 13485, and GMP remains critical for market access and product legitimacy.
  • Technology Trends: Enhanced membrane customization and biocompatibility are driving competition.
  • Future Outlook: Growing demand in emerging markets combined with technological advancements will diversify supply sources and increase competition.

Frequently Asked Questions (FAQs)

1. How do I verify the regulatory compliance of MEMBRANEBLUE suppliers?

Verify regulatory credentials through official certifications (FDA, CE, ISO 13485, GXP compliance). Request detailed certificates and audit reports during the qualification process.

2. Are there regional differences in the quality standards for MEMBRANEBLUE?

Yes. North American and European suppliers generally adhere to stricter standards such as FDA and EMA regulations, whereas Asian suppliers may comply with local standards like CDSCO but are increasingly aligning with global norms.

3. What factors influence the cost of MEMBRANEBLUE?

Key factors include material complexity, membrane customization, production volume, regulatory requirements, and logistic costs.

4. How sustainable is the supply chain for MEMBRANEBLUE?

Leading suppliers have diversified manufacturing locations and robust logistics networks. However, regional disruptions—such as those caused by geopolitical tensions or pandemics—can impact supply, emphasizing the need for multi-source sourcing strategies.

5. Can suppliers customize MEMBRANEBLUE for specific medical applications?

Yes. Many suppliers offer membrane customization in porosity, thickness, surface modification, and surface topography to suit specific medical needs like dialysis, wound healing, or tissue engineering.


References

  1. FDA Medical Devices Database. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
  2. European Medicines Agency (EMA). https://www.ema.europa.eu/en
  3. ISO 13485 Standard. International Organization for Standardization, 2016.
  4. GMP Guidelines for Medical Devices. U.S. FDA, 2022.
  5. Market Reports on Medical Membranes. Allied Market Research, 2023.

End of Document

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.